Interpretation of core content regarding 2023 China guidelines for the management of blood lipids
-
摘要: 近年来血脂领域的重要成就有目共睹，新认知、新靶点与新药物的快速发展，使血脂异常在心血管疾病管控中的作用日渐突出。《中国血脂管理指南(2023年)》(简称新指南)于2023年3月修订发布，为中国心血管疾病的防治再添重要的指导性文件。本文简要介绍新指南的修订背景及整体内容的核心要点，以期更为简洁和快速的传递新指南的基本精神，为中国人群的血脂管理及心血管疾病的防治提供参考。Abstract: A great progression has been made in recent years with respect to the lipid filed and the fresh knowledges, novel targets and new medications have been developed, which make an outstanding role of lipid in the management and control of cardiovascular diseases(CVD). Notably, 2023 China guidelines for the management of blood lipids[New guideline], a guiding file for the prevention and treatment of CVD in Chinese population, have been published in March 2023. The present article reviews the revised background and key points of new guideline for the purpose of spreading the knowledges more rapidly and simply, which may help to provide a reference for the prevention and treatment of CVD in Chinese population.
-
Key words:
- lipid /
- management /
- guideline /
- cardiovascular disease
-
-
[1] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(3): 221-255. https://xuewen.cnki.net/CCND-CFNB202305230080.html
[2] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1): 111-188. doi: 10.1093/eurheartj/ehz455
[3] Li JJ, Ma CS, Zhao D, et al. Lipoprotein(a)and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement[J]. JACC Asia, 2022, 2(6): 653-665. doi: 10.1016/j.jacasi.2022.08.015
[4] Li JJ, Liu HH, Li S. Landscape of cardiometabolic risk factors in Chinese population: a narrative review[J]. Cardiovasc Diabetol, 2022, 21(1): 113. doi: 10.1186/s12933-022-01551-3
[5] Li JJ, Liu HH, Wu NQ, et al. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects[J]. Expert Opin Drug Metab Toxicol, 2020, 16(9): 837-851. doi: 10.1080/17425255.2020.1802426
[6] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation, 2019, 139(25): e1082-e1143.
[7] Cao YX, Dou KF, Li JJ. Remnant cholesterol as a lipid-lowering target may have long way to go[J]. Eur Heart J, 2023: online.
[8] Li JJ, Dou KF, Zhou ZG, et al. Role of omega-3 fatty acids in the prevention and treatment of cardiovascular Diseases: A consensus statement from the Experts'Committee Of National Society Of Cardiometabolic Medicine[J]. Front Pharmacol, 2022, 106992.
[9] Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: Guidelines and new therapies[J]. Atherosclerosis, 2018, 277: 483-492. doi: 10.1016/j.atherosclerosis.2018.06.859
[10] Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Pane[J]. Eur Heart J, 2017, 38(32): 2459-2472. doi: 10.1093/eurheartj/ehx144
-
计量
- 文章访问数: 6073
- PDF下载数: 5318
- 施引文献: 0
下载: